David A. Siegel Apellis Pharmaceuticals, Inc. Call Options Transaction History
Two Sigma Advisers, LP
- $42.8 Billion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|---|---|---|---|---|
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
Others Institutions Holding APLS
# of Institutions
291Shares Held
124MCall Options Held
921KPut Options Held
761K-
Wellington Management Group LLP Boston, MA12.3MShares$247 Million0.05% of portfolio
-
Avoro Capital Advisors LLC New York, NY12.2MShares$245 Million4.32% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$238 Million20.45% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$203 Million0.0% of portfolio
-
Morgan Stanley New York, NY9.63MShares$193 Million0.02% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $2.2B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...